✦ LIBER ✦

Clinical trial endpoints: angiograms, events, and plaque instability

✍ Scribed by Christie M. Ballantyne

Book ID: 113979921
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 120 KB
Volume: 82
Category: Article
ISSN: 0002-9149
DOI: 10.1016/s0002-9149(98)00591-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sizing clinical trials with variable end

Sizing clinical trials with variable endpoint event rates

✍ Lemuel A. Moyé 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

Although many researchers in cardiovascular clinical trials have disciplined themselves to execute sample size calculations in the design of their studies, these computations become difficult in the presence of control group endpoint event rate uncertainty. Recent experience in cardiovascular clinic

Clinical trials design: protocols and en

Clinical trials design: protocols and endpoints

✍ Wyllie, M G 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB

Sample sizes for clinical trials with ti

Sample sizes for clinical trials with time-to-event endpoints and competing risks

✍ Gabi Schulgen; Manfred Olschewski; Vera Krane; Christoph Wanner; Günther Ruf; Ma 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Biomarkers and surrogate endpoints in cl

Biomarkers and surrogate endpoints in clinical trials

✍ Thomas R. Fleming; John H. Powers 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Choosing endpoints in clinical studies a

Choosing endpoints in clinical studies and trials

✍ Chauhan, B C 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 89 KB

Endpoints and clinical trial design for

Endpoints and clinical trial design for nonalcoholic steatohepatitis

✍ Arun J. Sanyal; Elizabeth M. Brunt; David E. Kleiner; Kris V. Kowdley; Naga Chal 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present,